BRAF(V600E)-targeted drugs (including Vemurafenib, PLX-4720, Dabrafenib, and SB-590885) have been effectively used for the treatment of colon cancer, thyroid cancer, and melanoma with the BRAF(V600E) mutation [68–71]. Here, BRAF is linked to thyroid gland carcinoma.